Moderna reiterates 10% revenue-growth target as Covid vaccine demand falls

Moderna reported falling fourth-quarter sales as Covid-19 vaccine demand continued to drop, but continues to target 10% ...

Moderna Just Crushed Estimates While Everyone Was Looking the Other Way

Moderna (NASDAQ: MRNA) reported fourth-quarter results Friday morning that beat Wall Street’s muted expectations, delivering ...
Just The News

Moderna threatens American jobs after FDA snubs mRNA flu shot, trial looked 'scientifically lax'

Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...
Fierce Biotech

UPDATE: After Moderna's rebuke, HHS stands behind FDA decision to spurn mRNA flu filing

"The FDA rejected Moderna's application for filing because the company refused to follow very clear FDA guidance from 2024 to ...

Moderna’s work developing seasonal vaccines is ‘risky’ under current FDA, analyst says

The biotech company said the FDA won’t review its flu vaccine, in the latest hit to mRNA development.
Blockonomi

Moderna (MRNA) Stock Slips Despite Beating Q4 Revenue and Earnings Estimates

Moderna (MRNA) stock fell 0.3% Friday despite beating Q4 revenue estimates at $678M and posting narrower loss of $2.11/share after FDA rejected flu vaccine review.
Fierce Biotech

Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg

In 2025, Moderna spent $3.1 billion on R&D, a 31% decrease from the $4.5 billion budget (PDF) in 2024 and a further drop from ...

Wall Street eyes Moderna earnings after FDA rebuff

Moderna will report its fourth-quarter 2025 earnings this morning in an investor call that’s taken on even more interest in ...